Skip to content

Search

Trial of new antibody gives hope to children suffering from brain cancer

Children with aggressive brain cancers could soon have access to a significant new treatment option, using a unique antibody that stops cancer cells from repairing themselves.

Homeward bound: The Kids Research Institute Australia researcher taking on scientific leadership challenge

The Kids Research Institute Australia researcher, Dr Anya Jones, will join some of the world’s brightest female scientists after being selected to take part in a global project to amplify the voices of women in science leadership.

Cancer Council WA supports development of less toxic treatments for childhood brain cancer

The Kids Research Institute Australia researcher, Dr Raelene Endersby, will work to develop less toxic treatments for children with brain cancer, thanks to support from Cancer Council WA.

The Kids Research Institute Australia Cancer Centre Researcher wins Cancer Council WA Fellowship

Cancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.

The Kids Research Institute Australia Cancer Researcher recognised in 2021 Business Events Perth Aspire Awards

One of The Kids Research Institute Australia’s leading young researchers will travel to the world’s premier conference on childhood brain cancer.

“Natural killer” donor cells fighting kids leukaemia

New research by The Kids shows donor immune cells are highly effective at boosting the body’s response against leukaemia.

Child health research set to benefit from national grants

Researchers at The Kids Research Institute Australia have been awarded $4.6 million in national funding from the National Health and Medical Research Council (NHMRC) and Medical Research Future Fund (MRFF) to help support child health research.

SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors

Pineal parenchymal tumors are rare neoplasms for which evidence-based treatment recommendations are lacking. These tumors vary in biology, clinical characteristics, and prognosis, requiring treatment that ranges from surgical resection alone to intensive multimodal antineoplastic therapy.

Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201

Our international team highlights issues with efficacy reports in several studies on DMG with the new drug ONC201.

KMT2A-rearranged acute lymphoblastic leukaemia

KMT2A-rearranged acute lymphoblastic leukaemia (ALL) represents a high risk subtype of childhood ALL. Historical treatment strategies have comprised of intensification with conventional chemotherapy. However, outcomes have remained consistently poor compared to the advances that have been seen for other ALL subtypes, particularly for infants diagnosed before their first birthday